Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease

Abstract

Co-administration of a long-acting β₂-agonist and a long acting muscarinic antagonist produces superior bronchodilation compared with their individual effects. Our preclinical data indicated that combining aclidinium bromide (ACLI) and formoterol fumarate (FORM) provides synergistic benefit on smooth muscle relaxation of both large and small human airways. Data from more than 2,000 patients in eleven clinical trials documented that ACLI/FORM, a twice-daily fixed-dose combination, produces a greater degree of bronchodilation than ACLI or FORM monotherapy alone and is safe and well tolerated. Two large key trials have shown that there is a benefit in using ACLI/FORM when the clinical target is the variability of symptoms and mainly nighttime and/or early morning symptoms. ACLI/FORM is the only long acting muscarinic antagonist/long acting β₂-agonist fixed-dose combination that has been studied for this therapeutic indication.

Keywords:

• aclidinium
• formoterol
• fixed-dose combination
• COPD
• symptoms

Disclosure

MG Matera reports receiving personal fees from Almirall. A Sanduzzi reports receiving personal fees from Almirall and AstraZeneca. M Cazzola reports receiving grants and personal fees from Almirall and AstraZeneca.